• Founded: 2015
  • Location: South SF, CA
  • Employee range: 11 - 50
  • Clinical stage: Clin1a
  • Therapy area: Severe alcoholic hepatitis
  • Drug types: HEP, GI, IMM, OPH, GEN
  • Lead product: SZN-043
  • Product link:
  • Funding: $50M Jun 2020; $50M Mar 2019; $33M A Feb 2017
  • Investors: Horizons Ventures, Hartford HealthCare Endowment, NS Investment, The Column Group

job board

Short description:

Wnt signaling antibodies

Drug notes:

SZN-1326 Clin1a IBD; SZN-413 Clin0 retinopathies; 2 undisclosed programs RD dry eye/Sjogren's, Fuch's dystrophy

Long description:

Contact us to add description:


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy